Article

Pathogenic Variants in BRIP1, RAD51C, and RAD51D Identified with Multi-Gene Panel Testing for Hereditary Cancers

2020-05-13

Abstract excerpt

<h4>Background: </h4> Professional society guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) for women with pathogenic variants (PVs) in ovarian cancer-risk genes. Personalization of that intervention is based on gene-specific phenotypes; however, the age of ovarian cancer diagnosis in women with PVs in moderate penetrance ovarian cancer-risk genes is not well characterized. Women who had hereditary...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e3ad2190-0ded-59cd-b23f-a1dbdec90c8c
DOI: 10.21203/rs.3.rs-27547/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pathogenic Variants in BRIP1, RAD51C, and RAD51D Identified with Multi-Gene Panel Testing for Hereditary CancersDOI 10.21203/rs.3.rs-27547/v1Read

Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.Semantic proximity Read

Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read

UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.Semantic proximity Read

Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene.Semantic proximity Read

Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).Semantic proximity Read

BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.Semantic proximity Read

The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review).Semantic proximity Read

Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian CancerSemantic proximity Read

Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.Semantic proximity Read

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Semantic proximity Read

Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?Semantic proximity Read

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.Semantic proximity Read